Identification of Global and Ligand-Specific Calcium Sensing Receptor Activation Mechanisms

Andrew N. Keller, Irina Kufareva, Tracy M. Josephs, Jiayin Diao, Vyvyan T. Mai, Arthur D. Conigrave, Arthur Christopoulos, Karen J. Gregory, and Katie Leach

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia (A.N.K., T.M.J., J.D., V.T.M., A.C., K.J.G., K.L.); Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, San Diego, California (I.K.); and School of Life and Environmental Sciences, Charles Perkins Centre (D17), University of Sydney, New South Wales, Australia (A.D.C.)

ABSTRACT
Calcium sensing receptor (CaSR) positive allosteric modulators (PAMs) are therapeutically important. However, few are approved for clinical use, in part due to complexities in assessing allosteracy at a receptor where the endogenous agonist (extracellular calcium) is present in all biologic fluids. Such complexity impedes efforts to quantify and optimize allosteric drug parameters (affinity, cooperativity, and efficacy) that dictate PAM structure-activity relationships (SARs). Furthermore, an underappreciation of the structural mechanisms underlying CaSR activation hinders predictions of how PAM SAR relates to in vitro and in vivo activity. Herein, we combined site-directed mutagenesis and calcium mobilization assays with analytical pharmacology to compare modes of PAM binding, positive modulation, and agonism. We demonstrate that 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-1-propanamine (NPS R568) binds to a 7 transmembrane domain (7TM) cavity common to class C G protein-coupled receptors and used by L-R(−)-α-methyl-N-[3-[3-[trifluoromethyl]phenyl]propyl]-1-naphthalenemethanamine (cinacalcet) and 1-benzothiazol-2-yl-1-(2,4-dimethylphenyl)-ethanol (AC265347); however, there are subtle distinctions in the contribution of select residues to the binding and transmission of cooperativity by PAMs. Furthermore, we reveal some common activation mechanisms used by different CaSR activators, but also demonstrate some differential contributions of residues within the 7TM bundle and extracellular loops to the efficacy of the PAM-agonist, AC265347, versus cooperativity. Finally, we demonstrate some differential contributions of residues within the 7TM bundle and extracellular loops to the efficacy of the PAM-agonist, AC265347, versus cooperativity. Finally, we show that PAMS potentiate the affinity of divalent cations. Our results support the existence of both global and ligand-specific CaSR activation mechanisms and reveal that allosteric agonism is mediated in part via distinct mechanisms to positive modulation.

Introduction

The human calcium sensing receptor (CaSR) is a class C G protein-coupled receptor (GPCR) that negatively regulates parathyroid hormone secretion in response to serum extracellular calcium (Ca^{2+}) concentrations. As such, the small-molecule positive allosteric modulator (PAM), L-R(−)-α-methyl-N-[3-[3-[trifluoromethyl]phenyl]propyl]-1-naphthalenemethanamine (cinacalcet), is approved for the treatment of secondary hyperparathyroidism, and for some instances for the treatment of primary hyperparathyroidism (Nemeth and Goodman, 2016). Cinacalcet has also been used off-label to correct disorders caused by naturally occurring loss-of-function CaSR mutations (Mayr et al., 2016). Although various CaSR small-molecule PAM chemotypes have been discovered, cinacalcet remains the only one on the market. Failure to translate newer CaSR PAMs to the clinic may reflect complexities associated with detecting and quantifying in vitro allosteric modulator effects at class C GPCRs (Leach and Gregory, 2017), thus hampering structure-activity relationship (SAR) optimization efforts and predictions of in vivo drug efficacy, and impeding dissection of allosteric mechanisms of action. For instance, despite cinacalcet being the first clinically approved GPCR allosteric modulator to reach the market, surprisingly little is known about how cinacalcet and other PAMs mediate positive allosteric modulation and/or agonism at the CaSR. Understanding GPCR activation mechanisms can help guide SAR optimization of ligands with desired activity.

Structural studies of class A and B GPCRs indicate that during receptor activation a rotational and vertical movement of transmembrane (TM) 6 and TM7 relative to TM3 occurs,
resulting in conformational changes at the intracellular face of
the receptor that promote transducer coupling (reviewed in de
Graaf et al., 2017; Manglik and Kruse, 2017). For class C
GPCRs, most endogenous agonists predominantly bind in the
large extracellular Venus flytrap (VFT) domain, stabilizing
activating conformational rearrangements that transmit
through the 7 transmembrane domain (7TM) spanning re-
gions and/or extracellular loops (ECLs) to the intracellular
side of the receptor. Many synthetic molecules that target
class C GPCRs bind to allosteric sites in the 7TM domain
and/or ECL regions. Furthermore, for the CaSR, the 7TM
and/or ECL domains also contain additional binding sites for
endogenous agonists including polyamines and Ca\textsuperscript{2+}
(Ray and
Northup, 2002; Leach et al., 2016). However, the 7TM
molecular mechanisms that underlie class C GPCR allosteric
(and indeed orthosteric) activation are largely unknown. This
is due to a complete lack of active-state class C GPCR 7TM
structures, but also, in part, due to the difficulties in
interpreting mutation-based structure-function studies to de-
lineate residue contributions to the three key molecular
properties that govern allosteric activity; ligand affinity, cooperativity, and efficacy.

In light of the difficulties associated with studying GPCR
allosteric modulator effects, we developed pharmacological and analytical methods to robustly quantify allosteric modu-
lation of GPCRs (Leach et al., 2007), and recently employed
these methods to probe class C GPCR allostery (Gregory et al.,
2012, 2013, 2014; Leach et al., 2016). We demonstrated
unprecedented insights into class C GPCR drug actions by combining pharmacological, analytical, and detailed
structure-function analyses. For instance, we identified a
CaSR 7TM domain cavity that accommodates small-
molecule CaSR PAMs and negative allosteric modulators,
and showed that structurally diverse modulators bind to
distinct regions in this cavity; the arylalkylamine PAM,
cinacalcet, and/or AC265347, their cooperativity with Ca\textsuperscript{2+}, or both (Leach et al., 2016), are shown in blue, red, and orange, respectively. All engineered mutations were
substituted with alanine, with the exception of A6151.42, A7725.39, A8407.35, and A8441.3, which were substituted with valine, and E8377.32, which was mutated to aspartic acid and isoleucine. The residue highlighted in green indicates where a naturally occurring mutation alters the activity of some PAMs (Cook et al., 2015). Arrows point to the \( \times 0.5 \) conserved class C amino acid residues based on a modified Ballesteros-Weinstein numbering system (Doré et al., 2014).

Given the importance of understanding the structural basis
underlying ligand binding and activation mechanisms at class C
GPCRs, the current study sought to build on our prior analysis of
CaSR allostery by examining the structural basis of positive
allosteric modulation mediated by the small-molecule PAM, 3-(2-
chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine
(NPS R568). The binding of NPS R568 and other arylalkylamine
PAMs is predicted to overlap with the cinacalcet binding site.
Given that arylalkylamine PAMs display comparable in vitro
pharmacology, we hypothesized that NPS R568 would demon-
strate similar structure-function relationships to cinacalcet. We
also hypothesized that the PAM-agonist, AC265347, mediates
agonism via engagement of residues that transmit positive

![Fig. 1. Studying positive allosteric modulation at the CaSR.](image)
modulation. Thus, we used mutagenesis to compare mechanisms of positive allosteric modulation and direct allosteric agonism mediated by NPS R568 and AC265347 (Fig. 1A). We identify both global and ligand-specific activation mechanisms at the CaSR, which could inform future drug discovery efforts seeking to rationally optimize the activity of CaSR activators and/or potentiators.

Materials and Methods

Materials. Dulbecco’s modified Eagle’s medium, blasticidin S HCl, and fetal bovine serum were obtained from Invitrogen (Carlsbad, CA), while hygromycin B was obtained from Roche (Mannheim, Germany). The Flp-In TReX human embryonic kidney 293 cells and Fluo-4 AM acetoxyethyl ester were purchased from Invitrogen. Quikchange mutagenesis kits were purchased from Agilent Technologies (Santa Clara, CA). NPS R568 was prepared as described previously (Davey et al., 2012). AC265347 and all other chemicals were from Sigma Aldrich (St Louis, MO).

Generation and Maintenance of Cell Lines Expressing Wild-Type (WT) and Mutant CaSRs. The generation of DNA and cells stably expressing c-myc-tagged WT and mutant human CaSRs in pCDAO/fit/TO have been described previously (Davey et al., 2012; Leach et al., 2016). Cells were maintained in Dulbecco’s medium containing 5–10% fetal bovine serum, 200 μg/ml hygromycin B, and 5 μg/ml blasticidin S HCl.

Intracellular Calcium (Ca\textsuperscript{2+}) Mobilization Assays. Cells were seeded in clear 96-well plates coated with poly-D-lysine (50 μg/ml) at 80,000 cells/well and incubated overnight in the presence of 100 ng/ml tetacycline. The following day, cells were washed with assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl\textsubscript{2}, 10 mM D-Glucose, 10 mM HEPES, 0.1 mM CaCl\textsubscript{2}, 0.5% bovine serum albumin, and 4 mM propaned at pH 7.4) and loaded with Fluor-4 AM acetoxyethyl ester (1 μM in assay buffer) for 1 hour at 37°C. Cells were washed with assay buffer prior to the addition of fresh assay buffer. For interaction studies between Ca\textsuperscript{2+} and PAMs, modulators were coadded with Ca\textsuperscript{2+} and PAMs, which could inform future drug discovery efforts seeking to optimize the activity of CaSR activators and/or potentiators.

Data Analysis. All nonlinear regression analyses were performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA). Parametric measures of potency, affinity, and cooperativity were estimated as logEC\textsubscript{50} (Christopoulos, 1998). Interaction experiments between Ca\textsuperscript{2+} and allosteric modulators were fitted to an operational model of allosterism (Leach et al., 2007; Aurelio et al., 2012; Leach et al., 2016); therefore, the formation of this salt bridge was enforced in our docking studies by imposing a harmonic distance restraint between the corresponding atoms. The aryalkylamine docking proceeded by extensive conformational sampling of the ligands and the residue side chains lining the pocket in the internal coordinates in the presence of this distance restraint. All complexes were further refined by local minimization in the presence of distance restraints maintaining receptor secondary and tertiary structures, and inspected manually.

Results

Rationale for the Study. We have previously evaluated the effects of CaSR 7TM and ECL mutations on allosteric modulator activity using an interaction paradigm (Davey et al., 2012; Cook et al., 2015; Leach et al., 2016). Here, the effect of a CaSR PAM can manifest as: 1) modulation of the exogenously added agonist to stimulate the response, reflected by a change in the added agonist potency and/or E\textsubscript{max}; 2) modulation of ambient agonist present in the buffer, reflected by an increase in the baseline response and/or a shallowing of the agonist concentration-response curve; and 3) direct PAM-mediated agonism, also reflected by an increase in the baseline response (Davey et al., 2012; Cook et al., 2015; Leach et al., 2016) (Fig. 1B). In this work, we have extended our analysis to account for ambient Ca\textsuperscript{2+} ions present in the assay buffer. Including the ambient Ca\textsuperscript{2+} concentration in the
operational model of allosterism allows delineation of PAM-mediated increases in the vehicle (buffer) response due to agonism versus potentiation of ambient Ca\textsuperscript{2+} (eq. 1). Accordingly, we are now able to quantify and delineate the effect of CaSR mutations on PAM affinity (pK\textsubscript{B}), allosteric cooperativity with the orthosteric agonist (αβ), and allosteric agonism (τ\textsubscript{D}).

Using this analytical paradigm, we examined two tool compounds; NPS R568 and AC265347. NPS R568 (Fig. 1A) was among the first identified CaSR PAMs (Nemeth et al., 1998) and a precursor to cinacalcet, which is an approved clinical treatment of human hyperparathyroidism. Both PAMs display similar in vitro pharmacology (Cook et al., 2015), despite subtle differences in their chemical structure; although NPS R568 and cinacalcet share a three carbon aliphatic chain linked to a secondary amine, they differ in their terminal aromatics: chlorophenyl and methoxyphenyl groups in NPS R568 were replaced with tri-fluoromethylphenyl and naphthyl groups in cinacalcet. With these differences in mind, we aimed to examine the SAR of NPS R568 in comparison with cinacalcet in more detail. Furthermore, whereas cinacalcet and NPS R568 exhibit little agonism, the chemically distinct CaSR PAM, AC265347, is both a PAM and an agonist (a PAM-agonist) (Cook et al., 2015). We were, therefore, interested in elucidating the different activation mechanisms used by these chemically and pharmacologically distinct CaSR activators. Of further interest, AC265347 exhibits biased CaSR modulation when compared with cinacalcet, presumably via stabilizing different active states (Davey et al., 2012; Leach et al., 2013, 2016; Cook et al., 2015).

Therefore, in this work, we used mutagenesis in combination with an operational model of allosterism that explicitly accommodates ambient agonist levels (eq. 1), to characterize important features of NPS R568 binding and positive cooperativity, and to directly probe AC265347 agonism. 7TM and ECL mutations were selected based on those known to alter the affinity and/or cooperativity of cinacalcet and/or AC265347 (Fig. 1C).

**NPS R568 Binds to a Common 7TM Allosteric Binding Site.** We first confirmed that NPS R568 bound within the same 7TM cavity used by other arylalkylamine modulators (Leach et al., 1998) and a precursor to cinacalcet, which is an approved clinical treatment of human hyperparathyroidism. Both PAMs display similar in vitro pharmacology (Cook et al., 2015), despite subtle differences in their chemical structure; although NPS R568 and cinacalcet share a three carbon aliphatic chain linked to a secondary amine, they differ in their terminal aromatics: chlorophenyl and methoxyphenyl groups in NPS R568 were replaced with tri-fluoromethylphenyl and naphthyl groups in cinacalcet. With these differences in mind, we aimed to examine the SAR of NPS R568 in comparison with cinacalcet in more detail. Furthermore, whereas cinacalcet and NPS R568 exhibit little agonism, the chemically distinct CaSR PAM, AC265347, is both a PAM and an agonist (a PAM-agonist) (Cook et al., 2015). We were, therefore, interested in elucidating the different activation mechanisms used by these chemically and pharmacologically distinct CaSR activators. Of further interest, AC265347 exhibits biased CaSR modulation when compared with cinacalcet, presumably via stabilizing different active states (Davey et al., 2012; Leach et al., 2013, 2016; Cook et al., 2015).

Therefore, in this work, we used mutagenesis in combination with an operational model of allosterism that explicitly accommodates ambient agonist levels (eq. 1), to characterize important features of NPS R568 binding and positive cooperativity, and to directly probe AC265347 agonism. 7TM and ECL mutations were selected based on those known to alter the affinity and/or cooperativity of cinacalcet and/or AC265347 (Fig. 1C).

**NPS R568 Binds to a Common 7TM Allosteric Binding Site.** We first confirmed that NPS R568 bound within the same 7TM cavity used by other arylalkylamine modulators (Leach et al., 2016). We fitted NPS R568 interaction data at the WT and 7TM mutant receptors to an operational model of allosterism with ambient agonist to assess the impact of 7TM amino acid substitutions on NPS R568 affinity (pK\textsubscript{B}). WT and representative mutants are shown in Fig. 2 that exemplify the different profiles observed. Similar to our previous observations with cinacalcet (Leach et al., 2016), F6683.56A, F6843.36A, F6883.40A, E8377.32I, and I8417.36A mutations abolished NPS R568 activity or reduced
NPS R568 pK_B, whereas F8216.53A, E8377.32D, and A8447.39V increased NPS R568 pK_B (Fig. 2; Fig. 3A; Supplemental Fig. 1; Table 1). Furthermore, although the magnitude of NPS R568 potentiation of Ca^{2+} potency at the Y8256.57A mutant was reduced (Supplemental Fig. 1), a significant and maximal ~2-fold increase in Ca^{2+} potency was reached in the presence of 0.1 μM NPS R568, suggesting the PAM pK_B was increased. To confirm this finding, we performed interaction studies between AC265347 and NPS R568. We found that 0.1–10 μM NPS R568 caused a dextral translocation of the AC265347 concentration-response curve at the Y8256.42A mutant, with no apparent decrease in AC265347 E_max (Supplemental Fig. 2); although limitations in AC265347 solubility prevented determination of complete AC265347 concentration-response curves in the presence of the higher NPS R568 concentrations. Nonetheless, these findings suggest that the interaction between NPS R568 and AC265347 is competitive, or an allosteric interaction governed by extremely high negative cooperativity. In support of a competitive or highly negatively cooperative interaction, when AC265347 and NPS R568 interact at the Y8256.42A mutant were fitted to a modified Hill/Gaddum/Schild equation (Motulsky and Christopoulos, 2004; Langmead et al., 2006), the Schild slope was not significantly different from unity. Under these circumstances, the concentration of NPS R568 that shifts the AC265347 EC_{50} 2-fold is equal to the NPS R568 pK_B; this analysis confirmed that the NPS R568 pK_B was increased by the Y8256.57A mutation (Table 1). A similar increase in cinacalcet pK_B has been observed at this mutant (Leach et al., 2016). Our findings are consistent with NPS R568 binding in the 7TM cavity in a similar pose to cinacalcet, concordant with previous predictions that E8377.32 forms a hydrogen bond with the core secondary amine in arylalkylamine modulators (Petrel et al., 2003, 2004; Miedlich et al., 2004; Bu et al., 2008; Leach et al., 2016). With this interaction, the terminal naphthyl (cinacalcet) or methoxyphenyl (NPS R568) moiety extends downward, p-stacking with F6843.36 and forming hydrophobic interactions with F6682.56, F6883.40, and I8417.36.
There were, however, subtle differences in the effects of some mutations on NPS R568 $p_K_B$ when compared with cinacalcet. For instance, W8186.50A decreased, whereas E767ECL2A, A7725.39V, or V833ECL3A increased, cinacalcet $p_K_B$ (Leach et al., 2016); in contrast, these mutations had no significant effect on NPS R568 $p_K_B$ (Fig. 3A; Table 1). To better understand the differences in the $p_K_B$ effects of these mutations, we constructed a homology model of the CaSR 7TM domain based on the mGlu$_5$ TM structure (Christopher et al., 2015) and interrogated this model bound to NPS R568 in silico. Since the NPS R568 core consists of an arylalkylamine, whose secondary amine is predicted to interact directly with ASPET Journals on October 19, 2023 molpharm.aspetjournals.org Downloaded from
the cooperation of both NPS R568 and cinacalcet, suggesting contributions to a common network that transmits positive cooperation by structurally similar PAMs (Fig. 3, C and D). In contrast, six of the mutations that specifically reduce NPS R568 cooperativity by structurally similar PAMs (Fig. 3, C and D).

Identification of Global and Ligand-Specific Activation Mechanisms at the CaSR. Having identified the NPS R568 binding site and differentiated ligand-receptor interactions governing affinity and cooperativity, we next sought to compare activation mechanisms used by different CaSR activators. To do so, we first validated the ability of the operational model of allosterism with ambient agonist (eq. 1) to distinguish between PAMs (e.g., NPS R568) and PAM-agonists (e.g., AC265347). When applied to Ca$_2^{2+}$ versus NPS R568 interaction data, we found that the operational model of allosterism with ambient agonist fit the data best when the PAM was presumed to have no efficacy (i.e., the best fit value $t_B$ differed from zero, $P$ test; $P < 0.001$) (Fig. 2A; Tables 1 and 2). This agreed with our previous study showing that cinacalcet, NPS R568, and other structurally related PAMs demonstrate negligible intrinsic agonism (Cook et al., 2015). In contrast, and also consistent with our previous study (Cook et al., 2015), the interaction between Ca$_2^{2+}$ and the PAM-agonist AC265347 were fitted best when the model assumed AC265347 was an agonist (i.e., the best fit value for $t_B$ differed from zero, $P$ test; $P < 0.001$) (Fig. 4A; Table 2).

Importantly, reanalysis of these previously reported data with eq. 1 yielded similar estimates of AC265347 $pEC_{50}$ and log$\beta$ (Supplemental Table 1). Taken together, these findings demonstrate that our operational model of allosterism with ambient agonist can differentiate between two PAMs with different agonist activity. Therefore, we next assessed the impact of mutations on allosteric modulator efficacy, $\tau_B$, independently of positive cooperativity.

Alanine substitution of F684$^{3.36}$ or F688$^{3.40}$ was previously found to reduce Ca$_2^{2+}$ potency (Leach et al., 2016), and in the current study also abolished AC265347-mediated Ca$_2^{2+}$ mobilization in the presence of vehicle (while positive cooperativity with Ca$_2^{2+}$ was retained) (Fig. 4B; Supplemental Fig. 1; Tables 1 and 2). Using a tetracycline-inducible cell line, we titrated F684$^{3.36}$ and F688$^{3.40}$ receptor expression levels to establish the Ca$_2^{2+}$ pEC$_{50}$ under conditions where it should more closely reflect its affinity (i.e., in the absence of receptor reserve) (Supplemental Fig. 4). With reduced expression levels, Ca$_2^{2+}$ pEC$_{50}$ values at the F684$^{3.36}$ and F688$^{3.40}$ receptor expression levels to establish the Ca$_2^{2+}$ pEC$_{50}$ under conditions where it should more closely reflect its affinity (i.e., in the absence of receptor reserve) (Supplemental Fig. 4).
potency and AC265347 efficacy at the F6843.36A, F6883.40A, F6121.39A, L7765.43A, or V8176.49A mutants under conditions where WT and mutant cell surface expression levels are comparable (Leach et al., 2016) suggests these residues are important for the transmission of agonism imparted by both Ca²⁺ and AC265347. In contrast, W8186.50A, F6682.56A, A7725.39V, F8216.53A, Y8256.57A, V833ECL3A, A8407.35V, or I8417.36A did not reduce Ca²⁺ potency (several increased it), or with the exception of F6682.56A did not reduce cell surface expression (Leach et al., 2016), but they all abolished AC265347 efficacy (Fig. 4D; Table 2). Qualitatively, AC265347 enhanced Ca²⁺ mobilization in the presence of vehicle alone at certain mutations (see, for example, Fig. 4D); however, our analysis is consistent with these baseline increases being attributable to positive modulation of ambient cations in the buffer rather than intrinsic AC265347 efficacy (Supplemental Table 1). Therefore, these eight residues are critical for mediating agonism of AC265347, but not Ca²⁺.

Intriguingly, analysis of NPS R568 interactions with Ca²⁺ revealed two mutations (G670A ECL1A and A844V ECL3A) where there was a gain in allosteric agonism, as demonstrated by a significant increase in τB, but neither mutation enhanced AC265347 efficacy (Table 2). Combined with a comparison of mutations that influence Ca²⁺ potency (Supplemental Fig. 5) versus AC265347 efficacy (Fig. 5; Table 2), our findings indicate that some 7TM and ECL residues play a global role in agonism imparted by all classes of agonist (i.e., orthosteric and allosteric), whereas others contribute to ligand-specific receptor activation.

The finding that the G670A and A844V mutations significantly reduced NPS R568 cooperativity yet converted NPS R568 to a PAM-agonist was intriguing. Therefore, we next sought to compare the global and AC265347-specific activation residues with the AC265347 cooperativity networks previously established (Leach et al., 2016) to determine whether there were also distinctions between cooperativity versus agonism networks used by other PAMs. Two mutations (F6121.39A and L7765.43A) that increased AC265347 efficacy (Fig. 5, A and B) did not change positive cooperativity, whereas V8176.49A increased AC265347 efficacy while decreasing cooperativity. In contrast, the loss in AC265347 efficacy at F6682.56A was opposed by increases in cooperativity. Four mutations that decreased AC265347 cooperativity (A6151.42V, E767ECL2A, K831ECL3A, and A844V ECL3A) had no effect on AC265347 efficacy. Collectively, these data reveal differential contributions of residues within the 7TM bundle and ECLs to efficacy versus cooperativity.

CaSR PAMs Enhance the Affinity of Orthosteric Agonists. To confirm mutational effects on PAM efficacy predicted from our analysis of interaction data, we assessed the ability of NPS R568 or AC265347 to stimulate Ca²⁺ mobilization in the absence of ambient Ca⁴⁺ or Mg²⁺ at WT and select mutant receptors. We evaluated G670A ECL1A and A844V ECL3A mutations, where NPS R568 was predicted to gain agonist activity, and A8407.35V ECL3A as a representative mutation that decreased AC265347 efficacy (Table 2). Furthermore, we evaluated E8377.32D as a control, because this mutation had no effect on the efficacy of NPS R568 or AC265347. Where possible, we fit agonist concentration response data to an operational model of agonism (eq. 2) to determine agonist affinity and efficacy at WT and/or mutant CaSRs (Table 3).

In agreement with our previous evaluation of PAM agonism (Cook et al., 2015), up to 30 μM NPS R568 did not stimulate Ca²⁺ mobilization in the absence of ambient cations (Fig. 6A); due to limited solubility, it was not possible to test higher concentrations. Nonetheless, these findings confirm that NPS...
R568 exhibits negligible agonism at the CaSR. In contrast to WT CaSR, NPS R568 stimulated concentration-dependent Ca$^{2+}$ mobilization in the absence of ambient cations at G670ECL1A and A8447.39V (Fig. 6, B and C), suggestive of increased NPS R568 efficacy, as predicted by our operational model analysis that incorporated the presence of ambient cations (Table 2). However, the estimated NPS R568 $pK_B$ at the G670ECL2A mutant was significantly lower in the absence of ambient cations (Table 3) than in their presence (Table 1) ($P < 0.05$, two-way ANOVA with Sidak’s multiple comparisons). A similar trend toward a lower NPS R568 $pK_B$ in the absence of ambient cations was also observed at the A8447.39V mutant, but this did not reach significance. At E8377.32D and A8407.35V, NPS R568 exhibited negligible agonist activity, similar to WT CaSR and as predicted from our operational model of allosterism analysis.

In contrast to NPS R568, AC265347 stimulated relatively robust Ca$^{2+}$ mobilization at the WT CaSR in the absence of ambient cations (Fig. 6A; Table 3), indicative of intrinsic agonism. AC265347 was also an agonist at the G670ECL2A, E8377.32D, and A8447.39V mutants in the absence of ambient cations, although there was a small but significant decrease in its efficacy at A8447.39V (Fig. 6; Table 3). Consistent with our operational model of allosterism analysis, AC265347 efficacy was reduced at the A8407.35V mutant.

Similar to NPS R568 at WT CaSR and G670ECL2A, A8447.39V, E8377.32D, or A8407.35V mutants, AC265347 bound with lower affinity in the absence of ambient cations than in their presence ($P < 0.05$, two-way ANOVA with Sidak’s multiple comparisons). The difference in affinities suggests that CaSR PAMs bind preferentially when an orthosteric agonist simultaneously occupies the receptor. Since cooperative allosteric effects on affinity are reciprocal (and, therefore, affect both agonist and modulator) (May et al., 2007), the elevated PAM affinity in the presence of ambient cations is expected if the PAM also enhances the
affinity of the ambient cations. Thus, NPS R568 and AC265347 likely act, at least in part, by potentiating the affinity of divalent cations. This could occur if the PAMs stabilized the closed form of the VFT via allosteric interactions between the 7TM and VFT domains.

**Discussion**

The current study has used a structure-function approach combined with analytical pharmacology to probe CaSR 7TM domain and ECL residues that contribute to receptor activation and positive allosteric modulation. Importantly, by incorporating the presence of ambient agonist into an operational model of allosterism, we were able to delineate the contribution of residues to PAM intrinsic efficacy (agonism) independently of positive cooperativity (potentiation of the orthosteric agonist) and affinity. We found both ligand-specific and global activation networks within the CaSR ECLs and 7TM bundle. The fact that mutations in these regions of the receptor have substantial effects on both orthosteric and allosteric ligands highlights the pivotal role that the 7TM domain and ECLs play in transmitting activating stimuli.

### Table 3

Functional affinity ($pK_B$) and efficacy ($\log \tau_B$) parameters for NPS R568 and AC265347 determined in Ca$^{2+}$ mobilization assays in the absence of ambient divalent cations.

<table>
<thead>
<tr>
<th>Data are mean ± S.E.M. and 95% confidence intervals from the indicated number of independent experiments ($n$).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NPS R568</strong></td>
</tr>
<tr>
<td>$pK_B$ (95% CI)</td>
</tr>
<tr>
<td>WT</td>
</tr>
<tr>
<td>G670ECL1A</td>
</tr>
<tr>
<td>E8377.32D</td>
</tr>
<tr>
<td>A8407.35V</td>
</tr>
<tr>
<td>A8447.39V</td>
</tr>
</tbody>
</table>

CI, confidence interval; ND, not determined due to negligible efficacy and/or low affinity.

$^a$Significantly lower than in the presence of ambient divalent cations ($P < 0.05$, two-way ANOVA with Sidak’s comparisons post-test).

$^b$Significantly different from WT ($P < 0.05$, one-way ANOVA with Dunnett’s multiple comparisons post-test).

---

**Fig. 6.** CaSR PAMs bind with lower affinity in the absence vs. presence of ambient divalent cations, and exhibit differential efficacy at the 7TM domain and ECL mutants. Concentration-response curves to Ca$^{2+}$, NPS R568, and AC265347 were determined in Ca$^{2+}$ mobilization assays in the absence of ambient divalent cations to evaluate PAM efficacy (A–E). Representative mutants were chosen based on their ability to provoke NPS R568 efficacy (G670ECL1A and A8447.39V), reduce AC265347 efficacy (E8377.32D), or have no effect on PAM efficacy (E8377.32D). Data are mean ± S.E.M. pooled from at least four separate experiments performed in duplicate. Curves are the best fit of the data to eq. 2. Vehicle (buffer) is plotted as the smallest [Ca$^{2+}$] in accordance with the logarithmic scale.
irrespective of the location of the ligand binding site. Importantly, our ability to delineate mutation effects on cooperativity and efficacy reveals that positive cooperativity appears to be mediated in part by residues that are distinct to those that transmit allosteric agonism. For instance, A615.E2, E767.ECL2, and K831.ECL3 all contributed to the transmission of AC265347 cooperativity yet played no role in AC265347 efficacy. Conversely, F612.A and L776.A constrained AC265347 efficacy but not positive cooperativity. In other instances, there were opposing contributions of residues to cooperativity versus efficacy, as was observed for G670.ECL2 and A844.ECL2; mutation of these residues decreased NPS R568 cooperativity yet converted NPS R568 to an agonist. Similarly, V817.E increased AC265347 efficacy while decreasing cooperativity, where the opposite was true for F662.A.

Using mutagenesis to dissect the contribution of 7TM and ECL residues to NPS R568 affinity, we confirm that NPS R568 binds to an extended cavity in the CaSR's 7TM domain, much like cinacalcet, with key interactions between F684.A, F688.A, A537.E, and I841.E. We did, however, identify some subtle differences in the binding of NPS R568 and cinacalcet, likely attributed to their different terminal aromatic groups, permitting cinacalcet to occupy more space at the top and bottom of the binding pocket. Despite this, and the identification of a number of residues that differentially contribute to NPS R568 and cinacalcet cooperativity, these two PAMs from the arylalkylamine family are pharmacologically very similar (Cook et al., 2015). The differences in NPS R568 and cinacalcet SAR appear to be overcome by shared contributions of E767.ECL2, V817.E, Y829.E, A844.ECL2, and L848.ECL2 to their transmission of positive cooperativity. Importantly, E767.ECL2, V817.E, and A844.ECL2 are also critical for positive cooperativity mediated by the structurally distinct PAM-agonist AC265347, suggesting that these residues may contribute to a global allosteric activation network. Furthermore, mutation of these residues also increases Ca2+ potency, suggesting a reduction in the energy barrier to transition to an active CaSR 7TM domain that mirrors the effects of PAMs. In fact, greater than 70% of the 7TM/ECL mutations studied herein increase Ca2+ potency (Leach et al., 2016), supporting the idea that substitution of residues in the allosteric binding cavity lowers the activation barrier for Ca2+. Mutations that reduce Ca2+ potency (e.g., F684.A, F688.A, and E837.ECL2) were at residues critical to the binding of allosteric drugs. Collectively, the influence of these 7TM/ECL residues on both orthosteric agonist activity and small-molecule binding and agonism indicates that the 7TM allosteric binding site has evolutionary importance and raises the possibility that an endogenous allosteric modulator may act via this site.

With regards to mutational effects on agonism, it was of particular note that aside from L776.A and V817.E, which were important for the efficacy of both Ca2+ and AC265347, the majority of residues differentially contributed to orthosteric versus allosteric efficacy. This was demonstrated by the opposing effect of many mutations, which increased Ca2+ potency yet decreased AC265347 efficacy. We cannot exclude the possibility that changes in Ca2+ potency were due to altered Ca2+ affinity, but we did show this was not the case for F684.A and F688.A mutations (Supplemental Fig. 4). With the exception of E837.ECL2, which we postulate may bind Ca2+, it is unlikely that mutation of other residues in this pocket significantly alter Ca2+ affinity, given that four key Ca2+ binding sites are located in the receptor's VFT domain (Geng et al., 2016). Thus, our data support the existence of global and ligand-specific activation mechanisms in the CaSR's 7TM and ECL regions.

Another key finding of this study is the demonstration that CaSR PAMs act by potentiating the affinity of Ca2+. This is in contrast to other class C GPCR PAMs, which enhance orthosteric agonist-mediated efficacy but do not appear to potentiate their binding (Gregory et al., 2012). The significant loss in PAM affinity in the absence of ambient cations versus in their presence is reminiscent of the reciprocal interaction between Ca2+ and L-amino acids (Conigrave et al., 2000, 2004); structural studies suggest both ligands are bound to the CaSR's VFT domain to achieve a fully active receptor conformation (Geng et al., 2016; Zhang et al., 2016). However, unlike L-amino acids, our current and previous studies (Leach et al., 2016) demonstrate that small-molecule PAMs bind in an extended CaSR 7TM domain cavity.

Our findings have important implications for future drug discovery efforts at the CaSR. Cinacalcet use is restricted due to an adverse risk of hypocalcemia (Chonchol et al., 2009), in part caused by oversuppression of parathyroid hormone secretion along with stimulation of thyroid CaSRs and consequent calcitonin secretion, and/or suppression of Ca2+ reabsorption via activation of renal CaSRs (reviewed in Leach et al., 2014, 2015). There is consequently continued interest in developing CaSR activators with greater tissue selectivity. Indeed, weak (partial) agonists or PAMs would be expected to stimulate robust pharmacological responses only in tissues where strong stimulus-response coupling exists, such as high CaSR-expressing parathyroid cells. To date, no small-molecule CaSR agonists devoid of PAM activity have been identified, and there have been no reported efforts to examine the physiologic consequences of PAMs with different degrees of cooperativity. Furthermore, as demonstrated by AC265347, some PAMs also exhibit agonism, which may heighten adverse effects by further amplifying receptor signaling. A greater appreciation of the drivers of CaSR agonism versus allosteric potentiation may afford an opportunity to rationally tune in or tune out PAM and agonist activity.

In conclusion, the current study provides new insight into 7TM and ECL CaSR activation mechanisms. In the future, this information could facilitate rational structure-based design of novel CaSR activators whose pharmacological and consequent therapeutic properties could be optimized by fine-tuning their PAM and/or agonist activity.

Authorship Contributions
Participated in research design: Gregory, Leach.
Conducted experiments: Keller, Kufareva, Josephs, Diao, Mai, Gregory, Leach.
Performed data analysis: Gregory, Leach.
Wrote or contributed to the writing of the manuscript: Keller, Kufareva, Conigrave, Christopoulos, Gregory, Leach.

References